News Feed

Glenmark Pharmaceuticals Inc., USA launches Travoprost Ophthalmic Solution USP, 0.004% (Ionic Buffered Solution)

Mahwah, New Jersey, November 27, 2024: Glenmark Pharmaceuticals Inc., USA (Glenmark) is pleased to announce the launch¹ of Travoprost Ophthalmic Solution USP, 0.004% (Ionic Buffered Solution). Glenmark’s Travoprost Ophthalmic Solution USP, 0.004% is bioequivalent and therapeutically equivalent to the reference listed drug, Travatan Z®² Ophthalmic Solution USP, 0.004% of Sandoz, Inc.

According to IQVIA^TM sales data for the 12-month period ending September 2024, the Travatan Z® Ophthalmic Solution USP, 0.004% market³ achieved annual sales of approximately $66.2 million*.

Commenting on the launch, Jim Brown, Senior Vice President, Sales & Marketing said, “We are excited to announce the launch of Travoprost Ophthalmic Solution USP, 0.004%, growing our portfolio of prescription ophthalmic products. This addition highlights our commitment to meeting market needs and providing high-quality solutions for our customers.”

Glenmark’s current portfolio consists of 200 products authorized for distribution in the U.S. marketplace and 51 ANDA’s pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

-- End --

About Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The company has 11 worldclass manufacturing facilities spread across 4 continents, and operations in over 80 countries. In Vivo/Scrip 100 positions Glenmark amongst the Top 100 Companies Ranked by R&D and Pharmaceutical Sales, 2022; while Generics Bulletin/In Vivo places it in the Top 50 Generics and Biosimilars Companies Ranked by Sales, 2022. Glenmark’s Green House Gas (GHG) emission reduction targets have been approved in 2023 by the Science Based Target initiative (SBTi), making it only the second pharmaceutical company in India to achieve this. The organization has impacted 3.3 million lives over the last decade through its CSR interventions. For more information, visit www.glenmarkpharma.com. You can follow us on LinkedIn (Glenmark Pharmaceuticals) and Instagram (glenmark_pharma).

For more information, please contact
Udaykumar Murthy | corpcomm@glenmarkpharma.com | +91 9960377617

References:
¹Glenmark’s Travoprost Ophthalmic Solution USP, 0.004% is only approved for the indication(s) listed in Glenmark’s approved label.
²All brand names and trademarks are the property of their respective owners. 3Market includes brand and all available therapeutic equivalents. Note: IQVIA data obtained by Glenmark is only available for all approved RLD indications. Glenmark’s product is only approved for the indications listed in Glenmark’s approved label and is not marketed for all RLD indications.
*IQVIA^TM National Sales Perspectives: Retail & Non-Retail, September 2024

Glenmark Pharmaceuticals Inc., USA launches Travoprost Ophthalmic Solution USP, 0.004% (Ionic Buffered Solution)

Mahwah, New Jersey, November 27, 2024: Glenmark Pharmaceuticals Inc., USA (Glenmark) is pleased to announce the launch¹ of Travoprost Ophthalmic Solution USP, 0.004% (Ionic Buffered Solution). Glenmark’s Travoprost Ophthalmic Solution USP, 0.004% is bioequivalent and therapeutically equivalent to the reference listed drug, Travatan Z®² Ophthalmic Solution USP, 0.004% of Sandoz, Inc.

According to IQVIA^TM sales data for the 12-month period ending September 2024, the Travatan Z® Ophthalmic Solution USP, 0.004% market³ achieved annual sales of approximately $66.2 million*.

Commenting on the launch, Jim Brown, Senior Vice President, Sales & Marketing said, “We are excited to announce the launch of Travoprost Ophthalmic Solution USP, 0.004%, growing our portfolio of prescription ophthalmic products. This addition highlights our commitment to meeting market needs and providing high-quality solutions for our customers.”

Glenmark’s current portfolio consists of 200 products authorized for distribution in the U.S. marketplace and 51 ANDA’s pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

-- End --

About Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The company has 11 worldclass manufacturing facilities spread across 4 continents, and operations in over 80 countries. In Vivo/Scrip 100 positions Glenmark amongst the Top 100 Companies Ranked by R&D and Pharmaceutical Sales, 2022; while Generics Bulletin/In Vivo places it in the Top 50 Generics and Biosimilars Companies Ranked by Sales, 2022. Glenmark’s Green House Gas (GHG) emission reduction targets have been approved in 2023 by the Science Based Target initiative (SBTi), making it only the second pharmaceutical company in India to achieve this. The organization has impacted 3.3 million lives over the last decade through its CSR interventions. For more information, visit www.glenmarkpharma.com. You can follow us on LinkedIn (Glenmark Pharmaceuticals) and Instagram (glenmark_pharma).

For more information, please contact
Udaykumar Murthy | corpcomm@glenmarkpharma.com | +91 9960377617

References:
¹Glenmark’s Travoprost Ophthalmic Solution USP, 0.004% is only approved for the indication(s) listed in Glenmark’s approved label.
²All brand names and trademarks are the property of their respective owners. 3Market includes brand and all available therapeutic equivalents. Note: IQVIA data obtained by Glenmark is only available for all approved RLD indications. Glenmark’s product is only approved for the indications listed in Glenmark’s approved label and is not marketed for all RLD indications.
*IQVIA^TM National Sales Perspectives: Retail & Non-Retail, September 2024